ClinicalTrials.gg
TerminatedNCT03460548Updated Apr 20, 2020

REMOGEN® Omega Versus Cationorm® in the Treatment of Patients Suffering From Dry Eye

An interventional study of Remogen and Cationorm in Dry Eye, sponsored by TRB Chemedica. Terminated at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-04-20.

Sponsored by TRB Chemedica · Not applicable, Interventional, and Treatment

Why this study was terminated
low recruitment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Dry Eye Syndromes with a site in France — 13 open to participants now, 14 under way, none of them phase 3. Dry Eye Syndromes · France.

Enrollment
35th of 40
26 · median 81
Started
2018
with 1 other
No phase
28 of 47
9 open now
Registered
14th of 47
by date

Among the 47 studies in Dry Eye Syndromes with a site in France, this one is the 35th largest by enrollment of the 40 interventional ones that give a count, is one of 2 that started in 2018, is one of 28 with no phase, and was the 14th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

13 of the 47 studies in Dry Eye Syndromes with a site in France are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Dry Eye Syndromes with a site in France, or all of them as a file.
02

Study summary

The efficacy and safety of Remogen® Omega in the treatment of dry eye signs and symptoms will be investigated in comparison to Cationorm®.

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With at least a 3-month documented history of bilateral dry eye
  • With a score of ocular surface staining with fluorescein (OSSF) ≥ 4 and ≤ 9 on the Oxford scale
  • With at least one objective sign of tear deficiency
  • With Ocular Surface Disease Index (OSDI) score of ≥ 18

Exclusion criteria

Exclusion Criteria:

  • Refractive surgery within 12 months prior to selection
  • Any other ocular surgery or ocular trauma within 6 months prior to selection
  • Systemic or local use of one of the following medications: glucocorticosteroids, cyclosporine A, antibiotics, NSAIDs
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
26 participants (actual)

Study arms

  • Experimental
    Remogen

    Device: Remogen

  • Active comparator
    Cationorm

    Device: Cationorm

Interventions

  • DeviceRemogen

    instil 1 drop of the product in each eye, 4 times per day

  • DeviceCationorm

    instil 1 drop of the product in each eye, 4 times per day

06

What researchers measure

Primary outcomes

  1. OSSF

    Ocular surface staining with fluorescein (OSSF)

    Time frame: Day 28

07

Study locations

1 site
  • Quinze-Vingts Hospital
    Paris, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Apr 2019, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2018
First posted
Mar 9, 2018
StartActual
Mar 30, 2018
Primary completionActual
Apr 16, 2019
CompletionActual
Jun 12, 2019
Last update
Apr 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03460548
Lead sponsor
TRB Chemedica
Responsible party
Sponsor
First posted
Mar 9, 2018
Start date
Mar 30, 2018
Primary completion
Apr 16, 2019
Completion
Jun 12, 2019
Last update
Apr 20, 2020

Study contacts

Christophe Baudouin, MD, PhD
principal investigator · Quinze-Vingts Hospital, Paris, France

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion